Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Cost of Goods Sold | $2 | $2 | $1 | $1 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $0 | $0 | -$0 | $0 |
| % Margin | 8.9% | 8.5% | -4.3% | 7.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $1 | $0 | $0 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |